EU Clinical Trial Information System (CTIS)

Brand Logo

Brand Logo Light

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

To estimate the prevalence of EGFR mutation  in a representative sample of  patients with newly diagnosed stage IIIB/IV NSCLC in Spain (predominantly Caucasian ethnicity).

Epidemiological study to evaluate the prevalence of epidermal growth factor receptor (EGFR) mutation status in patients with newly diagnosed locally advanced or metastatic non small cell lung cancer (NSCLC)

Research Site

Epidemiological study to evaluate the prevalence of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC (stage IIIB/IV non-small cell lung cancer)

Epidemiological study to evaluate the prevalence of epidermal growth factor receptor (EGFR) mutation status in patients with newly diagnosed locally advanced or metastatic non small cell lung cancer (NSCLC) - Spanish REASON

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

CSR-NIS-OES-DUM-2009/1

CSR-NIS-OES-DUM-2009/1

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator